Why the study?
Many COVID-19 therapies were repurposed from other diseases, warranting a robust foundation regarding their cardiovascular outcomes to understand trial rationales and guide future drug repurposing.
This review highlights the potential cardiovascular adverse effects of repurposed COVID-19 therapies, emphasizing the need for careful monitoring, especially in patients with long COVID or pre-existing cardiovascular conditions.
Supports cardiac monitoring with COVID-19 therapies; extends adverse-event data to guide practice and future trials.
The COVID-19 pandemic has resulted in many therapies, of which many are repurposed and used for other diseases in the last decade such in Influenza and Ebola. We intend to provide a robust foundation for cardiovascular outcomes of the therapies to better understand the rationale for the clinical trials that were conducted during the COVID-19 pandemic, and to gain more clarity on the steps moving forward should the repurposing provide clinical benefit in pandemic situations. With this state-of-the-art review, we aim to improve the understanding of the cardiovascular involvement of the therapies prior to, during, and after the COVID-19 pandemic to provide meaningful findings to the cardiovascular specialists and clinical trials for therapies, moving on from the period of pandemic urgency.
No takes yet. Share an insight, caveat, or question.
Sarfraz et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: